Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

NICE Guidance - April 2016

The National Institute of Health and Care Excellence (NICE) have published new or updated guidance for the month of April 2016. This month there is one clinical guideline, one guideline and two technology appraisals that impact upon primary care.

The Depression in adults: recognition and management clinical guideline covers identification and management of depression in adults aged 18 years and older, in primary and secondary care. It aims to improve care for people with depression by promoting improved recognition and treatment. This guideline was updated to contain a link to the guidance on repetitive transcranial magnetic stimulation for depression

The Controlled drugs: safe use and management guideline covers systems and processes for using and managing controlled drugs safely in all NHS settings except care homes. It aims to improve working practices to comply with legislation and have robust governance arrangements. It also aims to reduce the safety risks associated with controlled drugs.

The Abiraterone technology appraisal reviews the place of this drug in treating metastatic hormone-relapsed prostate cancer before chemotherapy. Abiraterone in combination with prednisone or prednisolone is recommended, within its marketing authorisation, as an option in people who have no or mild symptoms after androgen deprivation therapy has failed, and before chemotherapy is indicated. This recommendation is made only when the manufacturing company rebates the drug cost of abiraterone from the 11th month until the end of treatment for people who remain on treatment for more than 10 months.

The Sacubitril / Valsartan technology appraisal reviews the place of this drug treating symptomatic chronic heart failure with reduced ejection fraction. Treatment is recommended as an option for people with New York Heart Association (NYHA) class II to IV symptoms and a left ventricular ejection fraction of 35% or less and who are already taking a stable dose of angiotensin‑converting enzyme (ACE) inhibitors or angiotensin II receptor‑blockers (ARBs).

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - April 2016' on Email Share 'NICE Guidance - April 2016' on Delicious Share 'NICE Guidance - April 2016' on Digg Share 'NICE Guidance - April 2016' on Facebook Share 'NICE Guidance - April 2016' on Google+ Share 'NICE Guidance - April 2016' on reddit Share 'NICE Guidance - April 2016' on StumbleUpon Share 'NICE Guidance - April 2016' on Twitter

SMC Update - April 2016

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Alendronic acid effervescent tablets (Binosto®) have been accepted for restricted use in the treatment of postmenopausal osteoporosis. The restriction limits use to patients who are unable to swallow tablets where alendronic acid is the appropriate treatment choice.

Camellia sinensis (Catephen®) has been accepted for restricted use in the cutaneous treatment of external genital and perianal warts (condylomata acuminata) in immunocompetent patients from the age of 18 years. The restriction limits use to patients not suitable for podophyllotoxin or who have not responded to treatment with podophyllotoxin.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - April 2016' on Email Share 'SMC Update - April 2016' on Delicious Share 'SMC Update - April 2016' on Digg Share 'SMC Update - April 2016' on Facebook Share 'SMC Update - April 2016' on Google+ Share 'SMC Update - April 2016' on reddit Share 'SMC Update - April 2016' on StumbleUpon Share 'SMC Update - April 2016' on Twitter

NICE Guidance - March 2016

The National Institute of Health and Care Excellence (NICE) have published new or updated guidance for the month of March 2016. This month there is one clinical guideline and one guideline that impact upon primary care.

The Antenatal care for uncomplicated pregnancies clinical guideline has been updated to remove two recommendations regarding gestational diabetes because this is now contained in the NICE guideline on Diabetes in pregnancy.

The Community engagement: improving health and wellbeing and reducing health inequalities guideline covers community engagement approaches to reduce health inequalities, ensure health and wellbeing initiatives are effective and help local authorities and health bodies meet their statutory obligations.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - March 2016' on Email Share 'NICE Guidance - March 2016' on Delicious Share 'NICE Guidance - March 2016' on Digg Share 'NICE Guidance - March 2016' on Facebook Share 'NICE Guidance - March 2016' on Google+ Share 'NICE Guidance - March 2016' on reddit Share 'NICE Guidance - March 2016' on StumbleUpon Share 'NICE Guidance - March 2016' on Twitter

SMC Update - March 2016

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Capsaicin (Quetenza®) has been rejected for the treatment of peripheral neuropathic pain in diabetic adults either alone or in combination with other medicinal products for pain. The manufacturer failed to make a submission.

Insulin detemir
(Levemir®) has been accepted for restricted use in the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. The restriction limits use to patients unable to achieve good glycaemic control with established insulins.

Oseltamivir (Tamiflu®) has been accepted for use in the treatment of influenza in children aged <1 year including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms.

Sacubitril / valsartan (Entresto®) has been accepted for use in adult patients for the treatment of symptomatic chronic heart failure with reduced ejection fraction. It was noted that sacubitril / valsartan, compared to an angiotensin-converting enzyme inhibitor (enalapril), significantly reduced rates of the composite outcome of cardiovascular death and hospitalisation for heart failure, rates of the component outcomes and of all-cause mortality.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - March 2016' on Email Share 'SMC Update - March 2016' on Delicious Share 'SMC Update - March 2016' on Digg Share 'SMC Update - March 2016' on Facebook Share 'SMC Update - March 2016' on Google+ Share 'SMC Update - March 2016' on reddit Share 'SMC Update - March 2016' on StumbleUpon Share 'SMC Update - March 2016' on Twitter

NICE Guidance - February 2016

The National Institute of Health and Care Excellence (NICE) have published new or updated guidance for the month of February 2016. This month there is one technology appraisal and six clinical guidelines that impact upon primary care.

The Ezetimibe technology appraisal recommends this treatment as monotherapy as an option for people with primary (heterozygous‑familial or non‑familial) hypercholesterolaemia who have a contraindication to or cannot tolerate a statin. It is also recommended for co-administration with a statin when cholesterol targets are not being met despite maximal statin therapy or when a change from initial statin therapy to an alternative statin is being considered.

The Motor neurone disease clinical guideline covers the assessment and management of motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care and includes recommendation on recognition and referral.

The Sunlight exposure clinical guideline covers how to communicate the risks and benefits of natural sunlight exposure (specifically, the ultraviolet rays UVA and UVB) to help people understand why they may need to modify their behaviour to reduce their risk of skin cancer and vitamin D deficiency. This guideline was also used to update the Skin cancer prevention public health guidance.

The Tuberculosis clinical guideline received a correction regarding identification of babies eligible for vaccination prior to birth, ideally through antenatal services.

The Bipolar disorder clinical guideline received an update to include a link to the Medicines and Healthcare Products Regulatory Agency’s (MHRA) toolkit to ensure female patients are better informed about the risks of taking valproate during pregnancy.

The Epilepsies clinical guideline received an update to include a link to the Medicines and Healthcare Products Regulatory Agency’s (MHRA) toolkit to ensure female patients are better informed about the risks of taking valproate during pregnancy.

The Attention deficit hyperactivity disorder clinical guideline received an update to the recommendations on dietary advice.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - February 2016' on Email Share 'NICE Guidance - February 2016' on Delicious Share 'NICE Guidance - February 2016' on Digg Share 'NICE Guidance - February 2016' on Facebook Share 'NICE Guidance - February 2016' on Google+ Share 'NICE Guidance - February 2016' on reddit Share 'NICE Guidance - February 2016' on StumbleUpon Share 'NICE Guidance - February 2016' on Twitter

« Older Posts

Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 787,939 spam comments.

atomic-wealth
fond-illness
summer